Evidence map›Paper›PMID 41584357›Full record

ArticleActa pharmaceutica Sinica. B2026

Binary pyroptosis-amplified self-assembling prodrug nanomedicine enhances immunogenicity and inhibits abdominal metastasis in ovarian cancer.

Feng Fang, Min Su, Xue Liu, Jing Chen, Qiwen Liu, Xinran Li, Xuanbo Zhang, Yuanyuan Chen, Huijiao Fu, Zhengchai Chen and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Feng FangDepartment of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 528100, China.
Min SuDepartment of Oncology, Guangzhou Development District Hospital, Guangzhou 510730, China.
Xue LiuDepartment of Laboratory Medicine, Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Innovative Molecular Imaging, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan 523018, China.
Jing ChenDepartment of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 528100, China.
Qiwen LiuDepartment of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 528100, China.
Xinran LiDepartment of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 528100, China.
Xuanbo ZhangDepartment of Laboratory Medicine, Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Innovative Molecular Imaging, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan 523018, China.
Yuanyuan ChenDepartment of Laboratory Medicine, Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Innovative Molecular Imaging, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan 523018, China.
Huijiao FuDepartment of Obstetrics and Gynecology, The First People's Hospital of Foshan, Foshan 528000, China.
Zhengchai ChenDepartment of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 528100, China.
Cao ZhouDepartment of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 528100, China.
Xuzi CaiDepartment of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 528100, China.
Zhengfen LiDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital, Southern Medical University, Guangzhou 510630, China.
Zhiqiang YuDepartment of Laboratory Medicine, Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Innovative Molecular Imaging, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan 523018, China.
Xuefeng WangDepartment of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou 528100, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer remains a formidable therapeutic challenge due to its high propensity for abdominal metastasis, recurrence, and the presence of an immunosuppressive tumor microenvironment. To overcome these obstacles, we developed a self-assembled nanoplatforms (OSN) by integrating a near-infrared semiconducting polymer with an oxaliplatin(IV) prodrug. This multifunctional design enables a synergistic triple-modality therapy-photothermal therapy (PTT), photodynamic therapy (PDT), and chemotherapy-within a single nanoparticle, effectively enhancing immunogenic cell death (ICD) and systemic antitumor immunity. Upon laser irradiation, OSN generates localized hyperthermia and reactive oxygen species. These effects synergistically enhance oxaliplatin activation and tumor penetration while triggering pyroptosis through dual caspase-1-mediated and caspase-3-dependent pathways. This robust pyroptotic response amplifies the release of damage-associated molecular patterns (

Indexed as

Abdominal metastasisAnti-tumor immunityMultimodal therapyNanomedicineOvarian cancerOxaliplatinPyroptosisSemiconducting polymer

Identifiers

PMID41584357
PMCPMC12828151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.